Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Busulfan bioavailability

M Hassan1, P Ljungman, P Bolme

  • 1Research Department, Huddinge Hospital, Stockholm, Sweden.

Blood
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydrops fetalis and failure of hematopoietic stem cell transplantation - A long route to the diagnosis of SPTA1-associated hereditary spherocytosis.

Blood cells, molecules & diseases·2022
Same author

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.

European journal of cancer (Oxford, England : 1990)·2021
Same author

Total body irradiation is a crucial risk factor for developing secondary carcinomas after allogeneic hematopoietic stem cell transplantation in childhood.

Neoplasma·2020
Same author

Can nature conservation and wood production be reconciled in managed forests? A review of driving factors for integrated forest management in Europe.

Journal of environmental management·2020
Same author

Blastic plasmacytoid dendritic cell neoplasm: First retrospective study in the Czech Republic.

Neoplasma·2020
Same author

Epidemiological Trends for Childhood and Adolescent Cancers in the Period 1994-2016 in the Czech Republic.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2019

Busulfan bioavailability varies significantly in children and adults undergoing bone marrow transplantation. Dosage adjustments based on body surface area and drug monitoring are recommended to optimize busulfan therapy.

Area of Science:

  • Pharmacology
  • Oncology
  • Pediatrics

Background:

  • Busulfan is a key drug in myeloablative therapy for bone marrow transplantation.
  • Altered busulfan disposition in children impacts treatment effectiveness and toxicity.
  • Variability in drug effectiveness and toxicity necessitates further pharmacokinetic studies.

Purpose of the Study:

  • To evaluate busulfan bioavailability in pediatric and adult patients.
  • To compare pharmacokinetic parameters, including clearance and distribution volume, between age groups.
  • To inform optimal busulfan dosing strategies in bone marrow transplantation.

Main Methods:

  • Oral bioavailability assessment in two patient groups: children (1.5-6 years) and older children/adults (13-60 years).
  • Intravenous administration to determine elimination half-life.

Related Experiment Videos

  • Calculation of busulfan clearance and distribution volume normalized to body weight and body surface area.

    • Main Results:

    • Significant interindividual variation in oral busulfan bioavailability observed in both groups.
    • Busulfan clearance and distribution volume normalized to body weight were significantly higher in children than adults.
    • No significant difference in clearance when normalized to body surface area, suggesting surface area as a better dosing metric.

    Conclusions:

    • Busulfan dosage calculation should prioritize body surface area over body weight for pediatric and adult patients.
    • Individualized busulfan dose adjustments and therapeutic drug monitoring are crucial to mitigate toxicity and improve outcomes.
    • Understanding pharmacokinetic differences is vital for optimizing busulfan therapy in transplantation.